# LITESPARK-001 (belzutifan): what clinicians are saying

> 87 statements from 16 sources (6 videos, 8 posts, 2 papers), 45 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026.

## Report

- Trial: A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
- NCT ID: NCT02974738
- Registry: https://clinicaltrials.gov/study/NCT02974738
- Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Phase: Phase 1
- Status: Active, not recruiting
- Drugs tested: belzutifan
- Indication: advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-21 UTC
- Last checked: 2026-11-21 UTC
- Release hash: 3ac35ab5d4e066e1e11e68f6838e01ebdf4184145ca831aea924c999bb0c5e32

## Counts

- Commentary sources screened: 26
- Sources cited by verified statements: 16
- Verified statements: 87
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 45
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Speakers cited: 14
- Cited speakers with a verified identity: 14
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 10
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 10
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Medical oncology
  - 2 physician, specialty not confirmed
  - 1 physician, Hematology and oncology
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

The clinicians cited read LITESPARK-001 as supporting further development because disease control persisted despite prior treatment. A medical oncologist described in the sources as presenting the results cautions against overinterpreting progression-free survival and hopes biomarker studies will explain variable responses. A urologist favors cabozantinib over everolimus for subsequent testing, whereas medical oncologists consider everolimus defensible after cabozantinib or axitinib. Comparative advantages in benefit or safety remain unproven.

## Question clinicians left open

What do clinicians say remains uncertain when interpreting PFS with belzutifan in heavily pretreated advanced clear-cell RCC from the single-arm LITESPARK-001 study?

From finding F1 (27 statements from 6 speakers in 13 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Late-line ccRCC: most speakers highlight responses; a clinician flags single-arm PFS
  - 27 statements from 6 speakers in 13 sources, 5 of them podcasts or videos.
  - 4 of the 6 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician flags single-arm PFS”.
  - 5 of the report's 10 cited clinicians.
- F2. Belzutifan safety: how speakers weigh anemia, hypoxia and manageability
  - 27 statements from 4 speakers in 11 sources, 6 of them podcasts or videos.
  - 4 of the 4 named speakers in this finding hold this view.
  - 3 of the report's 10 cited clinicians.
- F4. HIF-2 targeting: a clinician sees proof of principle but hopes for biomarker work
  - 14 statements from 1 speaker in 6 sources, 4 of them podcasts or videos.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “hope for biomarker work”.
  - 1 of the report's 10 cited clinicians.
- F5. Everolimus control: most speakers question it; some see prior-therapy logic
  - 11 statements from 7 speakers in 4 sources, 2 of them podcasts or videos.
  - 5 of the 7 named speakers in this finding hold this view; 3 of the 7 hold its caveat, “some see prior-therapy logic”.
  - 4 of the report's 10 cited clinicians.

### Beyond the trial population

- F6. Belzutifan: what speakers say
  - 14 statements from 5 speakers in 8 sources, 5 of them podcasts or videos.
  - 4 of the report's 10 cited clinicians.
- F8. XmAb819: what speakers say
  - 2 statements in 1 source.
  - No named clinician · accounts and unnamed speakers.

2 of the 6 findings and 12 of the 87 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 27 | 21 | 13 | 6 | 3 |
| F2 | 27 | 20 | 11 | 4 | 6 |
| F4 | 14 | 8 | 6 | 1 | 3 |
| F5 | 11 | 12 | 4 | 7 | 3 |
| F6 | 14 | 12 | 8 | 5 | 4 |
| F8 | 2 | 1 | 1 | 0 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 17 | 0 | 1 | 1 | 8 | 31 | 2 | 6 posts and articles, 5 podcasts and video, 2 publications |
| F2 | 12 | 0 | 1 | 4 | 10 | 29 | 1 | 3 posts and articles, 6 podcasts and video, 2 publications |
| F4 | 8 | 1 | 1 | 0 | 4 | 15 | 0 | 1 post or article, 4 podcasts and video, 1 publication |
| F5 | 8 | 1 | 0 | 1 | 1 | 14 | 0 | 1 post or article, 2 podcasts and video, 1 publication |
| F6 | 11 | 1 | 1 | 0 | 1 | 15 | 0 | 2 posts and articles, 5 podcasts and video, 1 publication |
| F8 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: maximum tolerated dose (MTD): F2 (3 shared claims)
- Population and setting: F1 (6 shared claims), F2 (1 shared claims), F4 (2 shared claims)
- The comparison: F1 (2 shared claims), F2 (4 shared claims), F4 (2 shared claims)
- Safety and tolerability: F1 (5 shared claims), F2 (17 shared claims), F4 (1 shared claims)
- Design and conduct: F1 (5 shared claims), F2 (1 shared claims), F4 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MTD: maximum tolerated dose
- NPI: National Provider Identifier, the US registry number for clinicians
- PFS: progression-free survival
- RCC: renal cell carcinoma

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 87 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 10 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 16 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 10 of the 14 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: maximum tolerated dose (MTD) | discussed | 3 | 1 |
| Population and setting | discussed | 7 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 6 | 5 |
| Safety and tolerability | discussed | 17 | 8 |
| Design and conduct | discussed | 6 | 4 |
| Activity, durability and the importance of prior treatment burden | discussed | 21 | 11 |
| Target rationale, scientific novelty and unresolved response or resistance | discussed | 13 | 5 |
| The subsequent phase III comparator debate | discussed | 10 | 4 |
| Post-IO positioning, combination development and research engagement | discussed | 13 | 6 |
| LITESPARK-013 as later dose-evaluation context | discussed | 3 | 1 |
| Use of the early cohort as a benchmark and questions after belzutifan exposure | discussed | 2 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 39 statements · 45%** | | | |
| YouTube | 35 | 5 | 5 |
| X videos | 4 | 1 | 1 |
| **Posts · 33 statements · 38%** | | | |
| X threads | 33 | 8 | 20 |
| **Primary sources · 15 statements · 17%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 15 | 2 | not screened |

- Screened window: 2018-06-01 to 2026-10-20
- Cited window: 2018-06-01 to 2026-10-20
- Retrieved: 2026-11-21

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
- Registry: NCT02974738 (https://clinicaltrials.gov/study/NCT02974738)
- Study IDs: 6482-001 · PT2977-101 (Pelaton Study ID) · MK-6482-001 (MSD)
- Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Design: Phase 1 · interventional, non randomized, single group, phase1
- Status: Active, not recruiting
- Enrollment: 120 (actual)
- Start: 2016-12-07 (actual)
- Primary completion: 2018-01-12 (actual)
- Primary endpoint: maximum tolerated dose (MTD) (3 Weeks)
- Intervention: Belzutifan (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 38 sources about other trials or topics are not included.
- Most substantive views concern previously treated or refractory clear-cell RCC. They cannot establish how clinicians interpret the trial's other solid-tumor or glioblastoma populations.
- Several accounts discuss the clinical setting and intervention without naming LITESPARK-001. Their views are preserved as attributed context rather than automatically treated as this trial's results.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Different dates, follow-up durations, adverse-event definitions and treatment-attribution categories limit direct comparison across reports. They do not by themselves establish a change in opinion or a contradiction.
- Early phase I/II activity and observational toxicity comparisons do not establish randomized efficacy or safety advantages. Personal long-duration treatment examples are not cohort medians.
- The subsequent phase III comparator debate, LITESPARK-013 dose comparison, combination studies and post-belzutifan sequencing arguments concern separate development questions and must not be assigned to LITESPARK-001's own arms or outcomes.
- No standalone protocol or exact belzutifan product label was reviewed. Supportive-care descriptions are study-management accounts, not a complete prescribing or routine-care assessment.
- Multiple posts, relays or publications may repeat the same underlying presentation or data and should not be counted as independent HCP agreement.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-21 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-21 UTC. No changes.

## Offer

- Size: Focused · 87 verified statements · 45 from 10 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (14 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/litespark-001-nct02974738
- Agents: POST https://www.erudio.com/api/orders with {"report": "litespark-001-nct02974738", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=litespark-001-nct02974738

## Cite

Erudio Health. LITESPARK-001 (NCT02974738): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/litespark-001-nct02974738

## Questions

### How much does the LITESPARK-001 report cost?

One edition costs $750 (Focused · 87 verified statements · 45 from 10 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the LITESPARK-001 report cover?

87 statements from 16 sources (6 videos, 8 posts, 2 papers), 45 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the LITESPARK-001 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "litespark-001-nct02974738" }) previews it and create_order({ "report": "litespark-001-nct02974738", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the LITESPARK-001 report?

Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/litespark-001-nct02974738.json
- Markdown: https://www.erudio.com/reports/litespark-001-nct02974738.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/litespark-001-nct02974738/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "litespark-001-nct02974738"}`
